Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma
Head and neck cancer affects nearly 750,000 patients, with more than 300,000 deaths annually. Advances in first line surgical treatment have improved survival rates marginally particularly in developed countries, however survival rates for aggressive locally advanced head and neck cancer are still p...
Guardado en:
Autores principales: | Farzaneh Kordbacheh, Camile S. Farah |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/df5a93e541f941bcab03629edb0b1449 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Epithelial-to-Mesenchymal Transition-Derived Heterogeneity in Head and Neck Squamous Cell Carcinomas
por: Philipp Baumeister, et al.
Publicado: (2021) -
Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
por: Hayashi N, et al.
Publicado: (2021) -
Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery
por: Karl Payne, et al.
Publicado: (2021) -
Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
por: Xuanli Xu, et al.
Publicado: (2021) -
Oral and Oropharyngeal Squamous Cell Carcinoma in Our Population: The Clinic-Pathological and Morphological Description of 153 Cases
por: Agarwal,A. K, et al.
Publicado: (2011)